Skip to Content
Merck
All Photos(8)

Key Documents

SAB4504427

Sigma-Aldrich

Anti-phospho-HER2 (pTyr877) antibody produced in rabbit

affinity isolated antibody

Sign Into View Organizational & Contract Pricing
All Photos(8)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 137 kDa

species reactivity

rat, mouse, human

concentration

~1 mg/mL

technique(s)

ELISA: 1:10000
immunohistochemistry: 1:50-1:100
western blot: 1:500-1:1000

NCBI accession no.

P04626

UniProt accession no.

P04626

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pTyr877)

Gene Information

human ... ERBB2(2064)

Immunogen

The antiserum was produced against synthesized peptide derived from human HER2 around the phosphorylation site of Tyr877.

Immunogen Range: 851-900

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Toshio Shimizu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5032-5040 (2014-08-12)
This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-hour intravenous (i.v.) infusion for 5 consecutive days every 2 weeks.
Yong Sang Hong et al.
PloS one, 9(10), e109440-e109440 (2014-10-29)
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired resistance to ERBB2 inhibition. To investigate this question we sought to characterize

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service